Clinical trial
Anti-Retrovirals for Kaposi's Sarcoma
NCT00444379 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00444379 |
|---|---|
| Title | Anti-Retrovirals for Kaposi's Sarcoma |
| Official title | A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa |
| Acronym | ARKS |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Institutes of Health (NIH) NIH Gilead Sciences Industry Abbott Merck Sharp & Dohme LLC |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kaposi's Sarcoma, HIV Infections |
| Intervention type | Drug |
| Interventions | Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir |
| Enrollment | 224 |
| Start date | Apr 1, 2007 |
| Primary completion | Feb 1, 2012 |
| Completion | Jul 1, 2012 |
| First posted | Mar 7, 2007 |
| Last update posted | Aug 20, 2014 |
| Countries | Uganda |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: